RxDoctor Payments Data

Elizabeth Phillips

Family · Pulaski, TNNPI 1316244643

Payments from drug & device makers

$1,320in general payments, 2019–2025

Across 79 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$315
  • AbbVie$313
  • AstraZeneca$164
  • Lilly USA, LLC$107
  • Otsuka America Pharmaceutical, Inc.$72
  • Nevro Corp.$66
  • plus $282 from 10 others

What the payments were for

  • Food & beverage$1,320100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,320 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$23,580
Medicare patients
61
Services billed
1,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$41,595
OzempicSemaglutide40$37,759
EliquisApixaban26$14,324
TrulicityDulaglutide12$11,797
TradjentaLinagliptin22$11,471
EntrestoSacubitril/Valsartan15$11,001
MyrbetriqMirabegron12$5,346
VyvanseLisdexamfetamine Dimesylate13$4,736
Breo ElliptaFluticasone/Vilanterol11$4,381
Ranolazine ErRanolazine12$2,040
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen92$1,501
Ventolin HfaAlbuterol Sulfate20$1,343
Colchicine14$1,145
Levothyroxine Sodium106$1,133
Potassium Chloride63$1,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$107$53,39152 claims
Novo NordiskOzempic$315$37,75940 claims
NovartisEntresto$33$11,00115 claims
Astellas Pharma US IncMyrbetriq$34$5,34612 claims
GSKBreo Ellipta$56$4,38111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Pulaski

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →